Singapore, March 5 -- Singapore-based startup ImmunoScape, an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, has announced the execution of a Memorandum of Understanding (MOU) with a premier NCI-designated Comprehensive Cancer Center in the United States (US), renowned globally for its pioneering history in cellular immunotherapy.

This partnership will fast-track ImmunoScape's "Seed and Boost" platform into the clinic. Concurrently, the company has announced a strategic investment from Leonardo DiCaprio.

Under the terms of the MoU, ImmunoScape will partner with the cancer centre to launch an investigator-initiated clinical trial targeting Wilms Tumor 1 (WT1) positiv...